Edition:
United Kingdom

Esperion Says Phase 3 Long-Term Safety Study Of Bempedoic Acid Met Primary Endpoint


Wednesday, 2 May 2018 

May 2 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 LONG-TERM SAFETY STUDY OF BEMPEDOIC ACID.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY IN LARGEST AND LONGEST DURATION STUDY.ESPERION - PATIENTS TREATED WITH BEMPEDOIC ACID ALSO ACHIEVED A SIGNIFICANT REDUCTION OF 22 PERCENT IN HIGH-SENSITIVITY C-REACTIVE PROTEIN. 

Related Company News

Company Quote

38.97
 --
19 Aug 2019